 |
|
|
| |
Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B (CHB): Primary endpoint results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)
|
| |
| |
AASLD 2023 nov 10-14
listen to live session
https://www.aasld.org/the-liver-meeting
Primary endpoint results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)
AASLD 2023 nov 10-14
|
| |
|
|
|
|
|
